Nonstructural Protein 4B Market to Reach $3,028.3 Million by 2035

Nonstructural Protein 4B market was valued at $967.1 million in 2025 and is expected to reach $3,028.3 million by 2035, registering a CAGR of 12.1% during the forecast period from 2026 to 2035. The sharp rise in dengue virus cases around the world has intensified research and clinical development efforts focused on targeting the viral nonstructural protein?4B, a validated point of intervention in the flavivirus replication cycle. As dengue burden expands, pharmaceutical and biotechnology organizations are prioritizing small?molecule NS4B inhibitors, both to address unmet therapeutic needs and to support diagnostic and research applications tied to NS4B. This surge in disease pressure directly fuels the Global Nonstructural Protein?4B Market by increasing investment in NS4B?related therapeutics and the associated demand for compounds, clinical trial activity, and NS4B?specific research reagents. Recent clinical progress with NS4B?targeted candidates further reinforces commercial interest and market momentum.

Browse the full report description of “Nonstructural Protein 4B Market Size, Share & Trends Analysis Report by Product Type (INO-8000, GSK-8853, PTC-725, RL-15A, and Other), and by Application (Hospitals, Clinics, Pharmaceutical Research and Development, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/nonstructural-protein-4b-market

Global surveillance data underscore the scale of this trend, with the World Health Organization reporting over 14.4?million dengue cases and more than 11?000 deaths in 2024, marking one of the highest annual burdens on record and reinforcing the need for targeted antiviral approaches. In the first four months of 2024 alone, more than 7.6?million cases were recorded, exceeding annual totals from many previous years and highlighting sustained transmission intensity. These elevated incidence figures amplify both clinical urgency and research investment, creating a measurable statistical backdrop for expanded NS4B?focused product development and commercial activity.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Product Type
  • Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Gilead Sciences, Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Nonstructural Protein 4B Market Report Segment

By Product Type

• INO-8000
• GSK-8853
• PTC-725
• RL-15A
• Other

By Application

• Hospitals
• Clinics
• Pharmaceutical Research and Development
• Others

Global Nonstructural Protein 4B Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/nonstructural-protein-4b-market